91Ë¿¹ÏÊÓÆµ

Event

Grand Rounds: ImmunotherapyÌýand Glioblastoma – The Odyssey Continues

Monday, May 11, 2026 08:00to09:15
De Grandpré Communications Centre

91Ë¿¹ÏÊÓÆµâ€™s Neurology Grand Rounds features weekly talks on a varietyÌý of clinical and research topics by both local and guest speakers. They are held weekly on Wednesday mornings.

Grand Rounds: Immunotherapy and Glioblastoma – The Odyssey Continues

Speaker: DavidÌýA. Reardon, M.D

To join this Zoom meeting, please register in advance

Microsoft Teams meeting
Join:
Meeting ID: 282 369 257 851 528
Passcode: EZ9iR3Rd

David A. Reardon, MD currently is a Professor of Medicine at Harvard Medical School, serves as Director of the Center for Neuro-Oncology at the Dana-Farber Cancer Institute where he is the inaugural recipient of the Alperin Family Chair in Neuro-Oncology .

He previously served as Clinical Director at the Center for Neuro-Oncology at Dana-Farber (12 years) and as the Associate Deputy Director of the Preston Robert Tisch Brain Tumor Center at Duke University Medical Center (11 years). He completed his residency at John Hopkins Hospital and his fellowship at the University of Michigan.

Dr. Reardon is an active researcher with special interests in the design and implementation of clinical trials for neuro-oncology and the preclinical evaluation of promising therapeutics for central nervous system tumors. His work includes using innovative clinical therapeutic agents to improve outcome for patients with brain and spinal tumors, with particular focus on immunotherapeutics. He has also led investigations of molecular-targeting agents, anti-angiogenic reagents, cytotoxins and other biologically-based therapies.

Dr. Reardon has published over 420 peer-reviewed manuscripts. He received the R. Wayne Rundles Award for Excellence in Cancer Research (Duke University, 2007) as well as the Award for Excellence in Adult Clinical Research by the Society for Neuro-Oncology in 2015 and 2016 and the James D. Griffin, MD Medical Oncology Team Science Award (DFCI, 2023). He has contributed to the training of 54 neuro-oncology fellows. He also served as the tenth president of the Society for Neuro-Oncology.

Ìý

Back to top